Neuroinflammatory Alterations in Treatment‐Resistant Depression Secondary to Long COVID by Repetitive Transcranial Magnetic Stimulation (rTMS): A Case Report

Back to table of contents Next article LETTERFull AccessNeuroinflammatory Alterations in Treatment‐Resistant Depression Secondary to Long COVID by Repetitive Transcranial Magnetic Stimulation (rTMS): A Case ReportShun Igarashi, MD, Kyoji Okita, MD, PhD, Daisuke Hayashi, MD, Ryuichi Yamazaki, MD, PhD, Yuki Matsuda, MD, PhD, Takamasa Noda, MD, PhD, Koichiro Watanabe, MD, PhD, Shinsuke Kito, MD, PhDShun Igarashi, MD, Kyoji Okita, MD, PhD, Daisuke Hayashi, MD, Ryuichi Yamazaki, MD, PhD, Yuki Matsuda, MD, PhD, Takamasa Noda, MD, PhD, Koichiro Watanabe, MD, PhD, Shinsuke Kito, MD, PhDPublished Online:1 Apr 2024https://doi.org/10.1176/appi.prcp.20230053AboutSectionsView articleSupplemental MaterialPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail View articleTo the Editor:COVID‐19 infection leads to various symptoms such as fatigue, difficulty concentrating, memory loss, anxiety, and depressed mood (1). We report the first case to our knowledge of a patient with treatment‐resistant depression secondary to COVID‐19 infection who was treated with repetitive transcranial magnetic stimulation (rTMS) and present neuroinflammatory alterations revealed by positron emission tomography (PET).A 39‐year‐old female, without a history of SARS‐COV‐2 vaccination nor depression, had contracted the COVID‐19 2 years ago. One year later, she had no core depressive symptoms such as depressed mood or loss of interest but went to outpatient clinics because of memory loss and severe fatigue. Despite treatments, her symptoms persisted for more than a year, and furthermore, she gradually presented with depressed mood, loss of pleasure, and difficulty concentrating. Diagnosed with depression, she did not respond to antidepressants including venlafaxine 150 mg/day. She came to our hospital for rTMS treatments. No structural abnormalities were observed on head magnetic resonance imaging. rTMS was administered over the left prefrontal cortex using the NeuroStar system (Neuronetics) at a frequency of 10 Hz with 120% motor threshold. She received 29 sessions over 6 weeks. No adverse events were observed. After the treatments, depressive symptoms with Hamilton Rating Scale for Depression‐17 scores improved from 20 to 7. A PET scan utilizing the translocator protein ligand [11C] DAA1106 (2) was performed before and after rTMS, which demonstrated that the standardized uptake value ratio of the neuroinflammatory marker [11C] DAA1106 was reduced in the whole brain (see Figure S1 and Table S1 in Online Supplement). The observed changes in each volume of interest ranged from 11.0% to 22.9%.rTMS is shown to be effective in patients with treatment‐resistant depression (3). The findings suggest that rTMS may have anti‐neuroinflammatory effects in improving depression, which is consistent with the microglial inflammatory hypothesis of depression (4). Microglial hyperactivation has been shown to be associated with persistent depressive and cognitive symptoms (5), raising the possibility that some symptoms secondary to COVID‐19 infection and subsets of treatment‐resistant depression may share a common pathophysiology. Further investigation is needed to confirm the reproducibility of the findings and elucidate the underlying mechanisms in a well‐designed study.Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan (S. Igarashi, K. Okita, D. Hayashi, T. Noda, S. Kito); Department of Neuropsychiatry, Kyorin University Faculty of Medicine, Tokyo, Japan (S. Igarashi, K. Watanabe); Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan (R. Yamazaki, Y. Matsuda, S. Kito) Send correspondence to Dr. Kito (kito@ncnp.go.jp)Dr. Yamazaki received personal fees from Inter Reha Co., Ltd., Dr. Matsuda received speaker's honoraria from Lundbeck Japan K.K., Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and Viatris Inc. Dr. Noda has received speaker's honoraria from Sumitomo Pharma Co., Ltd. and Takeda Pharmaceutical Co. Ltd., Viatris Inc. and research grants from Inter Reha Co., Ltd., Dr Watanabe received grants from Daiichi Sankyo, Eisai, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, speaker's honoraria from Boehringer Ingelheim, Eisai, Janssen Pharmaceutical, Kyowa Pharmaceutical, Lundbeck Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka, Pharmaceutical, Shionogi, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Viatris, and consulting fees from Boehringer Ingelheim, Daiichi Sankyo, Eisai, Janssen Pharmaceutical, Kyowa Pharmaceutical, Lundbeck Japan, Luye Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, Viatris, Dr. Kito received speaker honoraria from Inter Reha Co., Ltd., Lundbeck Japan K.K., Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and Viatris Inc.; consultant fees from Kyowa Pharmaceutical Industry Co., Ltd., Teijin Pharma Ltd., and Inter Reha Co., Ltd.; and research grants from Teijin Pharma Ltd., Dr. Igarashi, Dr. Okita and Dr. Hayashi have no COI to disclose.REFERENCES1 Lopez‐Leon S, Wegman‐Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long‐term effects of COVID‐19: a systematic review and meta‐analysis. Sci Rep. 2021;11(1):16144. https://doi.org/10.1038/s41598‐021‐95565‐8Google Scholar2 Ikoma Y, Yasuno F, Ito H, Suhara T, Ota M, Toyama H, et al. Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [(11)C] DAA1106. J Cereb Blood Flow Metab. 2007;27(1):173–184. https://doi.org/10.1038/sj.jcbfm.9600325Google Scholar3 Kan RLD, Padberg F, Giron CG, Lin TTZ, Zhang BBB, Brunoni AR, et al. Effects of repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex on symptom domains in neuropsychiatric disorders: a systematic review and cross‐diagnostic meta‐analysis. Lancet Psychiatr. 2023;10(4):252–259. https://doi.org/10.1016/s2215‐0366(23)00026‐3Google Scholar4 Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, et al. The role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatr. 2015;72(3):268–275. https://doi.org/10.1001/jamapsychiatry.2014.2427Google Scholar5 Braga J, Lepra M, Kish SJ, Rusjan PM, Nasser Z, Verhoeff N, et al. Neuroinflammation after COVID‐19 with persistent depression and cognitive symptoms. JAMA Psychiatr. 2023;80(8):787–795. https://doi.org/10.1001/jamapsychiatry.2023.1321Google Scholar FiguresReferencesCited byDetailsCited byNone Metrics PDF download History Received 11 October 2023 Revised 19 January 2024 Accepted 23 January 2024 Published online 1 April 2024